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Abstract: The challenge posed by resistance among Gram-positive bacteria, epitomized by 
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) 
and vancomycin-intermediate and -resistant S. aureus (VISA and VRSA) is being met by a new 
generation of antimicrobials. This review focuses on the new β-lactams with activity against 
MRSA (ceftobiprole and ceftaroline) and on the new glycopeptides (oritavancin, dalbavancin, 
and telavancin). It will also consider the role of vancomycin in an era of existing alternatives 
such as linezolid, daptomycin and tigecycline. Finally, compounds in early development are 
described, such as iclaprim, friulimicin, and retapamulin, among others.
Keywords: Gram-positive bacteria, vancomycin, anti-MRSA cephalosporins, lipoglycopeptides, 
daptomycin, linezolid, tigecycline
Introduction
Bacterial resistance to antibiotics certainly does not represent a novel event. Since the 
introduction of benzylpenicillins (Figure 1.1), it has been observed that given enough 
time, bacteria will develop resistance to virtually any antibiotic introduced into clinical 
practice (Table 1). Currently, antibiotic resistance largely deﬁ  nes the epidemiology 
and pharmacologic therapy of infectious diseases. β-lactam resistant Gram-positive 
bacteria provide the best illustration of this phenomenon. The “persistent pathogen”, 
Staphylococcus aureus, is even more formidable since it manifested resistance to 
methicillin and other semi-synthetic penicillins, giving rise to the acronym “MRSA” 
(methicillin resistant S. aureus) (Sabath and Finland 1962). Presently, and perhaps 
in a more virulent fashion due to its association with Panton-Valentine leucocidin 
(PVL, an exotoxin active against neutrophils), MRSA has been implicated in a surge 
of community-acquired infections (CA-MRSA) that is reaching epidemic propor-
tions (Vandenesch et al 2003; King et al 2006; Voyich et al 2006; Labandeira-Rey 
et al 2007). Unfortunately, the entire class of β-lactam antibiotics currently in use is 
ineffective for the treatment of methicillin-resistant S. aureus (MRSA) infections. By 
virtue of its unique mechanism of action on the cell wall, vancomycin (Figure 1.5), the 
preeminent glycopeptide, became the antibiotic of “last resort” against resistant Gram-
positive bacteria. Unfortunately, Enterococcus spp. established itself in the 1990s as 
a “respected pathogen” in the nosocomial setting, more problematic than in the past 
because of its frequent resistance to vancomycin (vancomycin-resistant Enterococcus; 
VRE) (Murray 1990). This unwelcome development, together with the threat of the 
emergence of vancomycin-intermediate and -resistant S. aureus (VISA and VRSA) 
(Smith et al 1999), conspire to imperil the status of vancomycin as the “workhorse” 
antibiotic for the treatment of infections caused by Gram-positive bacteria.
Efforts to ﬁ  nd solutions to the “Gram-positive problem” have been fruitful. In the 
past decade, we witnessed the introduction into contemporary practice of oxazolidi-
nones (eg, linezolid [Stevens et al 2002] Figure 1.11), cyclopeptides (eg, daptomycin Infection and Drug Resistance 2008:1 28
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[Fowler et al 2006] Figure 1.9) and glycylcyclines (eg, 
tigecycline [Babinchak et al 2005; Ellis-Grosse et al 2005] 
Figure 1.12), new classes of antibiotics with in vitro and 
clinical activity against MRSA and VRE. Furthermore, the 
rational design of new drugs based on “old molecules”, the 
discovery of agents with novel mechanisms of action, and 
the innovative application of the principles of pharmaco-
kinetics (PK) and pharmacodynamics (PD) to improve the 
use of existent drugs, offer great promise. Thus, we are at 
an important time to review the new antibiotics and those 
that are in development which target resistant Gram-positive 
pathogens. This article will summarize: i) the new generation 
of antibiotics effective against Gram-positive bacteria based 
on the modiﬁ  cation of the parent β-lactam and glycopeptide 
structures; ii) the insights gained from the use of vancomy-
cin; iii) the experience accumulated with the introduction of 
recently developed classes of antibiotics in the clinical arena; 
and iv) novel compounds in development. We also offer a 
clinical perspective to these emerging issues as infectious 
disease physicians.
Figure 1 Chemical structures of select antibiotics active against Gram-positive cocci.
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Table 1 Timeline of introduction of antibiotics active against Staphylococcus aureus; ﬁ  rst report of resistance and description of mechanism 
of resistance
Antibiotic Introduction Resistance
reported
Mechanism of resistance References
Penicillin 1943 1945 β-lactamase Demerec 1945
Methicillin 1959 1961 Penicillin binding protein (PBP) 2a Barber 1961
Tetracycline 1950 1955 Efﬂ  ux pumps (tetK and tetL) and ribosomal 
protection proteins (tetM and tetO)
Brodie et al 1955
Vancomycin 1956 1997/2002 Abundance of D-alanyl D-alanine/shift to 
D-alanyl D-lactate
Hiramatsu et al 1997; 
Chang et al 2003
Trimethoprim 1965 1986 Mutation in dihydrofolate reductase Archer et al 1986
Linezolid 2000 2002 Mutations in 23S ribosomal RNA Pillai et al 2002
Daptomycin 2003 2005 Mutations in mprF, rpoB, and rpoC (unclear). Hayden et al 2005
Tigecycline 2005 NR NR
Abbreviation: NR, not reported.Infection and Drug Resistance 2008:1 32
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New β-lactams against MRSA
The construction of the peptidoglycan backbone of the Gram-
positive bacterial cell wall requires the polymerization of a 
polysaccharide chain formed by discaccharide-pentapeptide 
monomers, with alternating N-acetylglucosamine (NAG) 
and N-acetylmuramic (NAM) acid moieties, and cross-
linked by peptide bridges. Enzymes termed D-alanyl-D-
alanine transpeptidases mediate this last key step in the 
process. β-lactam antibiotics inhibit these enzymes, known 
as penicillin binding proteins (PBPs), by covalently binding 
to their serine site (Livermore 2006). Recent studies reveal 
that the bacterial peptidoglycan takes a helical shape with 
a deﬁ  ned periodicity (Meroueh et al 2006). These ﬁ  nding 
forms the basis of novel approaches to inhibiting cell wall 
synthesis in bacteria.
The identiﬁ  cation in 1961 in England of a strain of 
S. aureus resistant to methicillin marked the prelude of the 
end of β-lactam therapy against this organism. This strain 
spread successfully and rapidly in hospitals around the world, 
carrying the mecA gene that codes for PBP2a, which has very 
low afﬁ  nity to any of the existent β-lactams. MRSA has since 
become the nosocomial pathogen “par excellence”; now, 
almost ﬁ  ve decades later, we are in the midst of an epidemic 
of CA-MRSA that is changing the landscape of antimicro-
bial therapy. Translation from the laboratory to the clinic of 
β-lactams with the capacity to bind to PBP2a has become a 
therapeutic imperative. The current generation of anti-MRSA 
β-lactams, once approved for use by regulatory authorities 
after their validation in clinical trials, will represent a major 
breakthrough (Page 2006; Rossolini 2007).
The most advanced among these molecules is ceftobiprole 
(Figure 1.3) (Bush et al 2007). This “ﬁ  fth generation” cepha-
losporin demonstrates potent binding to PBP2a in MRSA 
(including VISA and VRSA [Bogdanovich et al 2005]), 
as well as to PBP2x in a penicillin-resistant Streptococcus 
pneumoniae strain and to PBP2 and PBP3 in Escherichia coli 
and Pseudomonas aeruginosa (Davies et al 2007). Addition-
ally, it has demonstrated activity similar to ampicillin against 
Enterococcus faecalis, including vancomycin-resistant and 
β-lactamase-producing isolates (Arias et al 2007); it is not 
active against Enterococcus faecium (Jones 2007) (Table 2). 
Although ceftobiprole is resistant to inactivation by a broad 
range of β-lactamases, it is hydrolyzed by extended-spectrum 
β-lactamases (ESBLs) found in Escherichia coli and 
Klebsiella spp. rendering its activity against Gram-negative 
bacteria comparable with that of cefepime (Queenan et al 
2007). The typical minimum inhibitory concentration (MIC) 
of ceftobiprole against MRSA is 2 µg/ml, contrasted with an 
MIC of   64 µg/ml for ceftriaxone. PK/PD studies in humans 
demonstrate that ceftobiprole has an elimination half-life of 
about 3 hours and predominantly urinary excretion (Murthy 
and Schmitt-Hoffmann 2008).
A phase 3 multi-centered, global, randomized, double-
blind trial comparing the efﬁ  cacy of ceftobiprole with that 
Table 2 Activity of different antibiotics against selected Gram-positive bacteria
Antibiotic MSSA MRSA VRSA VRE References
MIC50 MIC90 MIC50 MIC90 MIC range MIC50 MIC90
Vancomycin 1 1 1 1 32–1024  64  64 Zeckel et al 2000; Sader et al 2008b; Sievert 
et al 2008
Linezolid 2 2 2 2 2–4 1 2 Deshpande et al 2007; Sader et al 2008b; 
Sievert et al 2008
Daptomycin 0.25 0.5 0.25 0.5  0.5–2 2 4 Sader et al 2007, 2008b; Sievert et al 2008
Tigecycline 0.12 0.25 0.12 0.25 0.12 0.03 0.06 Bozdogan et al 2003; Hoban et al 2005; 
Gales et al 2008
Ceftobiprole 0.25 0.5 1 2 1 4 8 Swenson and Tenover, 2002; Bozdogan et al 
2003; Jones, 2007; Pillar et al 2008
Ceftaroline 0.25 0.25 1 2 Not reported 16  32 Sader et al 2005
Oritavancin 1 2 1 2 0.25b 1 2 Zeckel et al 2000; Bozdogan et al 2003
Dalbavancin 0.06 0.06 0.06 0.06 0.5b 4 32 Bozdogan et al 2003; Streit et al 2004; Jones 
et al 2006
Telavancin 0.5 0.5 0.25 0.5 2–4c 2 4 King et al 2004; Leuthner et al 2006
Abbreviations: MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S.  aureus; VRSA, vancomycin-resistant S.  aureus; VRE, vancomycin-resistant 
Enterococcus; MIC50, minimal inhibitory concentration for 50% of tested strains; MIC90, minimal inhibitory concentration for 90% of tested strains; MIC, minimal inhibitory 
concentration (µg/ml).Infection and Drug Resistance 2008:1 33
Antibiotics against Gram-positive bacteria
of vancomycin in patients with complicated skin and skin 
structure infections (CSSSI) caused by Gram-positive 
bacteria (MRSA, MSSA, Staphylococcus epidermidis, and 
β-hemolytic streptococci) showed that both drugs were 
equivalent. In this trial, 282 patients received ceftobiprole 
intravenously (IV) 500 mg every 12 h and were compared 
with 277 patients who received vancomycin 1 gram IV every 
12 h. Cure rates for patients with MRSA infections were 
91.8% (56/61) with ceftobiprole treatment and 90.0% (54/60) 
with vancomycin treatment (Noel et al 2008b). A second 
clinical trial comparing ceftobiprole monotherapy versus 
treatment with vancomycin plus ceftazidime was also carried 
out, with important variations (Noel et al 2008a). This design 
included patients with CSSSIs caused by Gram-negative 
bacteria (E. coli, P. aeruginosa, Klebsiella pneumoniae, 
Proteus mirabilis, and Enterobacter cloacae) in addition 
to Gram-positive bacteria. Thus, patients with diabetic foot 
infections could be included. A more frequent dosing scheme 
(ceftobiprole 500 mg IV every 8 hours), and a longer infu-
sion period (120 minutes vs. 60 minutes) were used. These 
modiﬁ  cations derived from PK studies that demonstrated a 
higher probability of achieving bactericidal and bacteriostatic 
targets with this dose; an important caveat derived from 
this data is that bactericidal concentrations against AmpC 
producing Enterobacteriaceae were not achievable (Lodise 
et al 2007). Clinical cure rates and microbiological outcomes 
were similar in both arms across the range of pathogens and 
CSSSIs. Of note, slightly worse outcomes (but similar in both 
arms) were observed in patients with diabetic foot infections 
and MRSA infections; the subgroup of patients infected with 
MRSA that expressed PVL had better outcomes when treated 
with ceftobiprole (although statistical signiﬁ  cance was not 
reported). Importantly, adverse events were rare among cef-
tobiprole-treated patients in both trials; a prolonged infusion 
time of 120 minutes caused a lower incidence of nausea and 
vomiting. Clinical trials evaluating the utility of ceftobiprole 
in the treatment of community- and hospital-acquired pneu-
monia (CAP and HAP, respectively) are underway.
A second cephalosporin with afﬁ  nity to PBP2a, ceftaroline 
(Figure 1.4), is also in development. It has demonstrated activ-
ity against MSSA, methicillin-resistant S. epidermidis and 
MRSA. When tested against a collection of CA-MRSA strains, 
the MIC50 and MIC90 were 0.5 µg/ml (Sader et al 2008a). Cef-
taroline is also active against strains of S. pneumoniae that 
are resistant to ceftriaxone, as well as Hemophilus inﬂ  uenzae 
and Moraxella catharralis. Similar to ceftobiprole, ceftaroline 
inhibited strains of both vancomycin-susceptible and -resistant 
E. faecalis, but was inactive against E. faecium. In contrast, 
its activity against Gram-negative bacteria is inferior to that 
of extended spectrum cephalosporins. Ceftaroline shows 
higher ranges of MICs against penicillinase-producing E. 
coli and Klebsiella spp. and Enterobacter, Citrobacter and 
Serratia spp. (0.12–1 µg/ml) than ceftriaxone, cefotaxime, 
ceftazidime, and cefepime. Ceftaroline is inactive against 
organisms producing ESBLs and AmpC β-lactamases; it is 
also inactive against anaerobes, Acinetobacter spp., and P. 
aeruginosa (Mushtaq et al 2007).
A phase 2 clinical trial evaluated the safety and efﬁ  cacy 
of ceftaroline in the treatment of CSSSI caused by aerobic 
Gram-positive bacteria, comparing it to “standard therapy” 
(vancomycin with and without aztreonam). The clinical cure 
rate was 96.7% for ceftaroline versus 88.9% for standard 
therapy, but this study was not powered for inferential sta-
tistical analysis (Talbot et al 2007).
A great deal of optimism also accompanies the develop-
ment of anti-MRSA carbapenems. These new compounds 
feature modiﬁ  cations to the carbapenem structure that have 
resulted in improved afﬁ  nity for PBP2a, among other PBPs. 
In contrast to ceftobiprole and ceftaroline, these molecules 
are also stable against Class A and C β-lactamases and there-
fore retain activity against Gram-negative bacteria producing 
extended-spectrum and AmpC cephalosporinases, as well as 
activity against anaerobes. These products have not been the 
subject of clinical trials yet. Some of the strongest candidates 
for further clinical development include: i) ME1036, which 
demonstrates very high afﬁ  nity to miscellaneous PBPs and 
is active in vitro against a broad collection of Gram-positive 
and Gram-negative isolates from the United States such as 
MRSA, penicillin-resistant S. pneumoniae, 3rd generation 
(extended-spectrum) cephalosporin-resistant Enterobacteria-
cea (ESBL and AmpC producing) and vancomycin-resistant 
E. faecalis, but not against vancomycin-resistant E. faecium; 
ii) PZ-601 (SMP-216601), which has been demonstrated 
in vitro activity against a similar collection of clinical 
strains from USA and Japan; iii) FSI-1297, also active in 
vitro against MRSA and vancomycin resistant E. faecalis 
(MIC = 1 µg/ml) but less potent against vancomycin resis-
tant E. faecium (MIC = 8 µg/ml); iv) RO4908463 (CS-023), 
active against MRSA and P. aeruginosa (47th Interscience 
Conference on Antimicrob Agents Chemother (ICAAC), 
Abstracts E-280, F1-341, A-29, Chicago, 2007.)
New glycopeptides in clinical 
development
Vancomycin (Figure1.5) belongs to the class of glycopep-
tides, a family of antibiotics produced by a diverse group of Infection and Drug Resistance 2008:1 34
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Actinomycetes. Other well-known representatives of this class 
include teicoplanin, widely employed around the world but not 
approved for use in the United States, and avoparcin, formerly 
used in Europe in animal husbandry. The chemical moiety 
that glycopeptides share in common is a heptapeptide. The 
heptapeptide backbone forms a carboxylate binding pocket 
that joins by forming hydrogen bonds to D-alanyl-D-alanine 
(D-Ala-D-Ala) peptidyl residues of the disaccharide-penta-
peptide monomers (composed of N-acetylmuramic acid and 
N-acetylglucosamine). This prevents the transpeptidation and 
transglycosilation reactions that the disaccharide-pentapeptide 
intermediates must undergo in order to polymerize and form 
the peptidoglycan cell wall. This ultimately leads to the inhibi-
tion of bacterial cell wall synthesis.
The best understood mechanisms of resistance against 
vancomycin is the elimination of the D-Ala-D-Ala binding 
target or the replacement of the terminal D-Ala by D-lactate 
(D-Lac) or D-serine (D-Ser), to which the heptapeptide 
cannot bind efﬁ  ciently (Courvalin 2006). Even though this 
represents the change of a single moiety, the enzymatic 
machinery necessary to produce it depends on a complex 
mechanism which involves the acquisition and regulation 
of several genes (eg, vanR, vanS, van H, vanA, vanX, vanY) 
through mobile genetic elements or transposons. This results 
in the expression of different phenotypes of glycopeptide 
resistance, denominated as VanA, -B, -C, -D, -E, and -G. 
For example, VanA denotes vancomycin and teicoplanin 
resistance associated with transposon Tn1546, found mostly 
among E. faecium and E. faecalis and described in S. aureus. 
VanB is vancomycin resistant but teicoplanin susceptible, 
and is associated with transposons Tn1547 and 1549. VanC 
differs in that it is not associated with a mobile genetic 
element but is intrinsic to Enterococcus gallinarum and 
casseliﬂ  avus, and depends on a shift of D-Ala to D-Ser (as 
opposed to D-Lac). An additional mechanism of resistance, 
the overexpression of D- Ala residues that results in inter-
mediate susceptibility to vancomycin, has been described in 
S. aureus (see below).
Despite sharing the same basic mechanism of action, 
the activity of glycopeptides against Gram-positive cocci 
is not homogeneous, probably explained by differences in 
their structure outside of the common heptapeptide moiety. 
These various structure – activity relationships among 
glycopeptides were exploited to develop a new generation 
of lipoglycopeptides that are able to overcome resistance 
to vancomycin, among which dalbavancin (Figure 1.6), 
telavancin (Figure 1.7), and oritavancin (Figure 1.8) are the 
more advanced representatives. The enhanced antibacterial 
activities of these lipoglycopeptides may derive from the 
ability of a hydrophobic side chain to cause both dimeriza-
tion and binding to bacterial membranes (Allen and Nicas 
2003). These cooperative interactions enhance binding at 
the traditional glycopeptide target. Additionally, the novel 
glycopeptides take advantage of alternative mechanisms 
of action; for instance, they may act by direct binding and 
inhibition of transglycosylation, inhibition of RNA and lipid 
synthesis or direct disruption of the membrane. The coexis-
tence of multiple mechanisms of action in one drug results 
in increased activity as demonstrated by lower MICs, when 
compared against vancomycin (Table 2). For example, the 
MIC of vancomycin against S. pneumoniae ranges from 0.25 
to 2 µg/ml, whereas for the new glycopeptides it ranges from 
0.002 to 0.12 µg/ml; the MIC for VanA and VanB Enterococ-
cus spp. drops eight-fold (Pace and Yang 2006).
Oritavancin (Figure1.8), the ﬁ  rst of the novel lipoglyco-
peptides, illustrates this search for compounds with improved 
spectrum and PK/PD characteristics based upon the existing 
structures of vancomycin and teicoplanin. The addition of a 
clorphenylbenzyl side chain (Figure 1) permits the dimeriza-
tion of oritavancin molecules and hydrophobic interactions 
with the bacterial membrane that facilitate binding to peptido-
glycan residues, even D-Ala-D-Lac (Allen et al 1997; Allen 
and Nicas 2003). Oritavancin demonstrates in vitro activity 
against Enterococcus spp., including VRE (VanA, VanB, and 
VanC), and Streptococcus (S. pneumoniae, S. pyogenes, S. 
agalactiae). It is also active against methicillin-susceptible 
S. aureus (MSSA) and MRSA, with MICs ranging between 
1–4 µg/ml, making it less potent than other glycopeptides 
(Table 2). Nevertheless, it is bactericidal against enterococci 
and staphylococci, unlike vancomycin (Lin et al 2005; 
Noviello et al 2001). Animal models suggest its activity is 
concentration dependent but a study in humans indicated that 
percentage of time above MIC was an important parameter 
of successful therapy in patients with S. aureus bacteremia 
(Boylan et al 2003; Bhavnani et al 2006). Because of its 
prolonged half-life, once daily dosing is feasible. There are 
no published clinical data on the use of oritavancin, but it 
is in development for the treatment of CSSSI. Despite its 
promise, there has been a several year hiatus in the develop-
ment of oritavancin.
Dalbavancin (Figure 1.6), derived from teicoplanin, is 
perhaps the most clinically advanced of the novel glyco-
peptides (Billeter et al 2008). In addition to binding to the 
D-Ala-D-Ala terminals of the growing peptidoglycan chain, 
dalbavancin interacts with the bacterial cell membrane, 
conferring it potent in vitro activity against MSSA, MRSA, Infection and Drug Resistance 2008:1 35
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S. pneumoniae, and β-hemolytic streptococci (Jones et al 
2006). Dalbavancin was equally potent against enterococci, 
including VRE but not VanA-resistant phenotypes (Jones 
et al 2005; Streit et al 2005). It is active against VRSA 
(Bozdogan et al 2003) and miscellaneous Gram-positive 
anaerobes (Goldstein et al 2006). Its unique characteristic is 
that it is intensely protein-bound, leading to an extended half-
life (mean 181 h), so that it can be dosed once weekly.
Phase 2 and phase 3 trials demonstrate equal effectiveness 
of dalbavancin in the treatment of CSSSI when compared 
with 14-day courses of vancomycin and linezolid, respec-
tively (Jauregui et al 2005; Seltzer et al 2003). A phase 2 
study of patients with staphylococcal (including MRSA) 
catheter-related bacteremias demonstrated superiority of 
dalbavancin administered twice daily for 14 days compared 
with vancomycin. Dalbavancin was administered at 1 gm on 
the ﬁ  rst day and then 500 mg on the eighth day of treatment 
in all of these trials. This unusual dosing schedule makes 
it a very appealing compound for outpatient therapy. The 
concern is the potential occurrence of adverse effects, which 
logically would also be long lasting given the long-half life 
of the compound. The above-mentioned studies, however, 
suggest a very favorable safety proﬁ  le.
Telavancin (Figure 1.7) is structurally similar to van-
comycin. The modiﬁ  cations on the original glycopeptide, 
namely the alkylation of the vancosamine substituent with a 
hydrophobic moiety, result in a multifunctional mechanism 
of action. The side chain promotes interaction with the cell 
membrane, improving afﬁ  nity for D-Ala-D-Ala and alter-
ing the bacterial cell membrane potential and permeability 
(Higgins et al 2005). This results in greater bactericidal activ-
ity and potency against staphylococci and enterococci, even 
VISA, VRSA, and VRE with Van A phenotype (Table 2). 
Similar to the other novel glycopeptides, telavancin has 
excellent in vitro activity against β-hemolytic streptococci 
and S. pneumoniae (Leuthner et al 2006; Clouse et al 2007; 
Jansen et al 2007). Additionally, when compared with van-
comycin, telavancin has a longer half-life (up to 9 h) so that 
it can be given once a day (Shaw et al 2005).
There are two published phase 2 clinical trials compar-
ing telavancin (dosed at 7.5 mg/kg/day and 10 mg/kg/day, 
respectively) against standard therapy with a β-lactam or van-
comycin for the treatment of CSSSI caused by Gram-positive 
bacteria. Overall, the outcomes were equivalent beween the 
two arms, except in the group with MRSA infection in which 
microbiological eradication and clinical cure appeared better 
in patients treated with telavancin (Stryjewski et al 2005, 
2006). Side effects consisted mostly of nausea and vomit-
ing; these occurred with equal frequency in the comparator 
arm. Further studies are underway to evaluate the efﬁ  cacy of 
telavancin in the treatment of pneumonia, which is supported 
by animal and preliminary human data (Gotfried et al 2008; 
Hegde et al 2008).
A novel compound, TD-1792, is described as a heterodi-
mer in which a cephalosporin moiety is covalently linked to 
vancomycin. TD-1792 therefore inhibits both key cell wall 
synthesis functions, transpeptidation and transglycosilation. 
It has demonstrated bactericidal activity against MRSA, 
with very low MICs (0.03 µg/ml). The administration of its 
individual components, the cephalosporin and vancomycin, 
by themselves or together (but not covalently linked) failed 
to achieve such good parameters of activity (47th ICAAC, 
Abstract F1-2110, Chicago IL, 2007). Its eventual use in the 
clinical arena depends on further development and clinical 
trials that support its efﬁ  cacy.
Enduring utility of vancomycin 
against S. aureus
There is an ongoing debate among clinicians regarding the 
continued utility of vancomycin for the treatment of infec-
tions caused by MRSA. Trusting more than 50 years of 
experience and an improved compound free of major toxici-
ties, physicians rely heavily on vancomycin. Furthermore, 
vancomycin retains activity against the vast majority of 
S. aureus isolates. In contrast, many have long considered 
vancomycin a sub-optimal antibiotic, for instance when 
compared with β-lactams for the treatment of MSSA. There 
is fear that vancomycin may be reaching obsolescence given 
the emergence of resistance. As argued in the recent point-
counterpoint arguments published in infectious diseases 
journals, there are many subtleties involved (Deresinski 
2007; Mohr and Murray 2007).
In contrast to Enterococcus spp., high-level resistance to 
vancomycin among S. aureus (MIC   16 µg/ml) has been 
reported only sporadically, amounting to seven cases (Sievert 
et al 2008), all from the United States. Analysis of the index 
case of VRSA from Detroit, Michigan in 2002 identiﬁ  ed 
the transfer of vanA, a vancomycin resistance determinant 
linked to Tn1546, from E. faecalis to S. aureus, a ﬁ  nding 
replicated in the subsequent six isolates (Chang et al 2003). 
Because the potential universal dissemination of VRSA has 
not materialized yet (Bush, 2004), the more common and 
immediate threat may be VISA (also referred to as glyco-
peptide intermediate S. aureus; GISA). First identiﬁ  ed in 
1996 in Japan and 1997 in the United States, VISA strains 
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the overproduction of D-Ala D-Ala or decreased turnover 
in the peptidoglycan wall that serve as a decoy target for 
vancomycin, resulting in MICs 4–8 µg/ml (Smith et al 
1999). Additionally, there is concern about the phenomenon 
of heteroresistance to vancomycin in S. aureus (hVISA). 
Subpopulations (MIC   2 µg/ml) exist within cultures of the 
same strain of S. aureus that are susceptible to vancomycin 
(MIC   1 µg/ml). Growth medium containing vancomycin 
selects for these subpopulations.
The gradual loss of S. aureus susceptibility to van-
comycin observed in a patient with MRSA endocarditis 
during unsuccessful treatment with vancomycin, is the 
origin of a remarkable collection of studies investigating 
VISA in vivo (McAleese et al 2006; Mwangi et al 2007; 
Sieradzki et al 2003; Sieradzki et al 1999). Tomasz and his 
group demonstrated the evolution of vancomycin resistance 
in S. aureus (from an MIC of 1 and 2 µg/ml to 8 µg/ml) 
through whole-genome sequencing, identifying the key 
mutations differentiating isogenic strains with progres-
sive increases in the MIC of vancomycin isolated from a 
single patient. Thirty-ﬁ  ve mutations appeared sequentially 
during the course of treatment. Furthermore, resistance 
to rifampin resulted as well, after administration of only 
one dose of this antibiotic. More intriguing, a 100-fold 
increase in the MIC of daptomycin (0.01 to 1 µg/ml) was 
observed, even though that antibiotic was not used as 
treatment. The mutations associated with these phenotypes 
were also identiﬁ  ed.
Sakoulas and colleagues revealed another important 
component that furthers our understanding of hVISA: the 
loss of function of the accessory gene regulator (agr) operon. 
Changes in this genetic element, identiﬁ  ed as the group II 
polymorphism, may confer higher MICs of vancomycin to 
S. aureus. This polymorphism is present in isolates with 
VISA and hVISA phenotypes and may be associated with 
vancomycin failure (Sakoulas et al 2003, 2005, 2006; Moise-
Broder et al 2004b).
The difﬁ  cult detection of hVISA in the microbiology 
laboratory hinders the assessment of the epidemiological 
and clinical impact of this phenotype. The method of refer-
ence, population-analysis proﬁ  le (PAP) testing, is laborious 
and resource intensive (Walsh et al 2001). Perhaps the best 
screening test for hVISA is the Etest macromethod, in which 
a high inoculum of bacteria (McFarland of 2) is used against 
Etest strips of vancomycin and teicoplanin (Voss et al 2007). 
The clinical impact of hVISA remains unclear. A study from 
Australia identiﬁ  ed ﬁ  ve patients with bacteremia caused by 
hVISA (deﬁ  ned by PAP); they were more likely to have high 
infections with high inoculum of bacteria, treatment failure 
and low vancomycin levels. A second survey by the same 
group looked at the outcomes of 25 additional patients with 
infections caused by S. aureus with reduced susceptibility to 
vancomycin; they had serious infections ranging from endo-
carditis to osteomyelitis, received prolonged and ineffective 
courses of vancomycin and had been previously infected with 
MRSA. It is difﬁ  cult to ascertain in both cases whether the 
detection of hVISA in these patients was a cause or an effect 
of the above-mentioned factors (Charles et al 2004; Howden 
et al 2004). Falagas and colleagues (2008a) reviewed the 
studies reporting the clinical outcome of infection with 
hVISA, and did not ﬁ  nd a consistent negative impact but 
rather conﬂ  icting results.
In 2006 the Clinical Laboratory Standards Institute 
(CLSI) lowered the vancomycin MIC breakpoints for 
S. aureus (from  4 µg/ml to  2 µg/ml for “susceptible,” 
from 8–16 µg/ml to 4–8 µg/ml for “intermediate,” and 
from  32µg/ml to  16 µg/ml for “resistant”) (Tenover 
and Moellering 2007). The rationale for this change was, 
among other considerations, to signal that strains with MICs 
close to 4 µg/ml (until then considered fully susceptible) are 
likely to be hVISA and therefore would go unrecognized 
by the microbiology laboratory and may be associated with 
vancomycin treatment failure. Moreover, there are reports of 
poor clinical outcomes associated with strains of S. aureus 
with MICs of 1–2 µg/ml, which is within the new susceptible 
range as determined by CLSI (Schwaber et al 2003; Sakoulas 
et al 2004). The application of a logistic regression model to 
a database of patients from Barcelona with MRSA bactere-
mia yielded similar results (Soriano et al 2008). Treatment 
with vancomycin in the instance of bacteremia caused by 
an isolate with a vancomycin MIC of 2 µg/ml – as deﬁ  ned 
by Etest – was a factor independently associated with mor-
tality. The database did not permit to assess the effect of 
serum vancomycin concentrations on outcomes, although 
the dosing regimen used in these patients targeted trough 
levels above 10 µg/ml.
The investigation of PK/PD parameters of vancomycin 
may clarify the association between heteroresistance and 
response to therapy. Studies have determined that the ratio 
of the area under the concentration-time curve to the MIC 
(AUC/MIC) predicts the clinical response to vancomycin 
(Rybak 2006). Furthermore, in pneumonia caused by MRSA, 
an AUC/MIC  400 is associated with a better clinical 
response (Moise-Broder et al 2004a). In contrast, a retrospec-
tive study on the dosing levels of vancomycin on MRSA 
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2006), demonstrated that vancomycin trough concentrations 
were similar in patients who lived and in patients who died 
(13.6 and 13.9 µg/ml, respectively). The investigators did not 
explore if the vancomycin MICs of the infecting strain may 
have had an impact on clinical outcome. However, PK data 
from this study showed that in order to achieve the above 
mentioned satisfactory AUC/MIC ratio of  400, both a high 
vancomycin trough concentration (approximately 20 µg/ml) 
and a low MIC of 0.5 µg/ml are required. Other investigators 
have shown that there may be an advantage in achieving 
vancomycin through concentrations  15 µg/ml within the 
initial 24 hours of treatment, but only in cases in which the 
infection is caused by strains with an MIC  2 µg/ml (Hidayat 
et al 2006). The American Thoracic Society guidelines for 
the treatment of HAP caused by MRSA recommend dosing 
vancomycin to achieve trough concentrations of 15–20 µg/ml 
(ATS 2005). This suggestion, however, does not derive from 
clinical studies evaluating the effect of vancomycin serum 
concentrations with respect to patient outcome and has to be 
balanced with a higher risk of adverse events in the form of 
renal dysfunction (47th ICAAC, Session 104, Paper K-1096, 
Chicago, IL). Recently, an in vitro pharmacodynamic model 
investigated different doses of vancomycin for the treatment 
of simulated moderate and high inoculum infections with 
hVISA. In cases of high inoculum infections, up to 105 cfu/ml 
of hVISA organisms (with MICs 2- to 4- fold higher than 
at their baseline) remained after the administration of doses 
of vancomycin as high as 5 g every 12 hours. This data may 
explain why treatment of high-inoculum infections caused 
by hVISA with vancomycin often results in failure (Rose 
et al 2008).
How does one reconcile the above observations in 
order to choose the appropriate therapy against MRSA 
infections in the clinic? We support the opinion that it is 
necessary to determine an accurate MIC of vancomycin in 
the microbiology laboratory, ideally with Etest or a broth-
based method, particularly in cases of MRSA infections 
with high organism loads (eg, pneumonia, endocarditis), 
in difﬁ  cult to reach compartments (eye, brain, etc), and 
in infections requiring prolonged treatment (endovascular 
infections). It can then be determined whether a satisfactory 
AUC/MIC ratio is achievable with aggressive vancomycin 
dosing regimens or if the use of an alternative antibiotic 
is preferable, a decision that needs to be modulated by the 
clinical response. Other strategies have been considered 
plausible improvements upon the limited performance of 
vancomycin against serious MRSA infections. Combina-
tion therapy with vancomycin and other agents has been 
attempted. A natural candidate has been rifampin, which 
is extremely bactericidal against S. aureus even in the 
intracellular compartment. Unfortunately, vancomycin 
is not able to neutralize rifampin’s notable proclivity to 
engender resistance (Simon et al 1983; Yamaoka 2007). 
Continuous infusion therapy, although promising for other 
antimicrobials, did not demonstrate increased effectiveness 
in the case of vancomycin in a randomized, multi-center 
study (Wysocki et al 2001; Kasiakou et al 2005). The pro-
spective evaluation of the above described strategies and 
other considerations is essential to help deﬁ  ne the continued 
utility of vancomycin, vis-à-vis newer antibiotics.
The experience with recently 
released antibiotics active against 
resistant Gram-positive cocci
The approval by the United States Food and Drug Admin-
istration (FDA) of linezolid, daptomycin, and tigecycline, 
each representative of a new class of antibiotics active 
against MRSA and enterococci offered welcome therapeutic 
alternatives to vancomycin. Linezolid, approved in 2000, and 
daptomycin, introduced in 2003, have emerged as the “anti-
biotics of last resort” for the treatment of infections caused 
by VRE. A newer addition, tigecycline, combines activity 
against S. aureus (including MRSA) and Enterococcus spp. 
with a broad spectrum of activity against Gram-negative and 
anerobic bacteria. The role of these three agents within the 
antibiotic armamentarium continues to evolve, shaped by 
their speciﬁ  c characteristics, the experiences of clinicians, 
and the performance of these drugs in clinical trials (Paterson 
2006; Micek 2007).
Linezolid (Figure 1.11) was the ﬁ  rst oxazolidinone 
released. By acting on the 50S ribosomal subunit, speciﬁ  -
cally the peptidyl-transferase center, linezolid blocks the 
binding of tRNA, interferes with protein synthesis and 
inhibits bacterial cell growth (Leach et al 2007). Line-
zolid is bactericidal against streptococci but bacteriostatic 
against MRSA and VRE in vitro. In contrast, a study car-
ried out in patients with diabetic foot infection caused by 
MRSA (some of them were additionally VISA or VRSA) 
demonstrated that serum can potentiate the antimicrobial 
effect of linezolid resulting in bactericidal activity (Stein 
et al 2007). Its near-complete oral bioavailability makes 
linezolid a tremendously attractive antibiotic for the 
treatment of suspected or conﬁ  rmed MRSA infections. 
In addition, linezolid offers the opportunity to potentially 
lower costs that result from hospitalization (McKinnon 
et al 2006). These advantages should be balanced with a Infection and Drug Resistance 2008:1 38
Perez et al
high cost as an oral agent, compared to generic alternatives 
widely used in the community. Patients on linezolid suf-
fer from neurological (peripheral neuropathy and optic 
neuritis) and hematological (anemia, leukopenia and 
thrombocytopenia) side effects resulting from the inhibi-
tion of mitochondrial protein synthesis, as well as drug-
drug interactions (serotonin re-uptake inhibitors) (Bishop 
et al 2006). Furthermore, resistance stemming from single 
nucleotide changes in varying numbers of copies of the 
genes encoding 23S ribosomal RNA has emerged during 
the course of treatment (Meka and Gold 2004).
An open label, multi-center, randomized controlled trial 
demonstrated that linezolid was superior to vancomycin in 
achieving microbiological cure in the treatment of CSSSIs 
due to MRSA (Weigelt et al 2005). However, additional 
trials are needed to conﬁ  rm this result and ascertain that 
clinical cure rates with linezolid exceed significantly 
those of vancomycin (Kalil et al 2006). Similarly, there 
is an ongoing controversy regarding the superiority of 
linezolid for the treatment of HAP and ventilator-associated 
pneumonia (VAP) caused by MRSA. Although the initial 
phase 2 randomized controlled trials showed equivalence 
between linezolid and vancomycin, further analysis of 
the same data showed that there was an advantage in 
survival in patients treated with linezolid; of note, the 
serum concentrations of vancomycin in patients included 
in these trials were not reported (Rubinstein et al 2001; 
Wunderink et al 2003). A recently published meta-analysis 
favored linezolid (Falagas et al 2008b), but appropriately 
designed and powered studies (phase 3 trials) are still 
needed to settle this question. Although it does not have 
FDA approval for the treatment of bloodstream infections, 
a pooled analysis of ﬁ  ve randomized studies comparing 
linezolid versus vancomycin for the treatment of S. aureus 
bacteremia demonstrated “noninferior” outcomes associated 
with linezolid (Shorr et al 2005). Stevens and colleagues 
(2007) observed that linezolid (as well as clindamycin) 
suppressed the translation in S. aureus of genes coding for 
extracellular protein toxins (eg, PVL, alpha-hemolysin, and 
toxic shock syndrome toxin 1). This supports the notion that 
linezolid not only inhibits bacterial growth but may also 
modulate the expression of virulence. Clinicians need to 
be careful about inferring a clinical advantage from these 
experimental ﬁ  ndings. Despite its utility, there are still many 
unanswered questions regarding the use of linezolid for its 
FDA-approved indications (the treatment of CSSSIs and 
HAP/VAP), as well as its role in the treatment of bacteremia 
and endocarditis (Falagas et al 2008b).
Daptomycin (Figure 1.9) is a cyclic lipopeptide antibiotic, 
unique in its class, with potent in vitro activity against Gram-
positive bacteria, including MRSA and VRE. Its mechanism 
of action is unclear but it seems to involve depolarization 
of the bacterial membrane and efﬂ  ux of potassium ions, 
leading to cell death (Steenbergen et al 2005). It is extremely 
bactericidal, even in instances of high inoculum/stationary 
phase infections, as demonstrated in bioﬁ  lm and endocarditis 
models (Rose et al 2007a; Roveta et al 2008). Even though 
it penetrates well into vascular structures and the urinary 
tract, daptomycin does not penetrate into the central nervous 
system and its use in the treatment of pneumonia is contra-
indicated because it is inhibited by pulmonary surfactant 
(Silverman et al 2005). It has been demonstrated to be safe, 
with only occasional elevations in creatine kinase observed 
(Kazory et al 2006).
The FDA approved the use of daptomycin for the 
treatment of CSSSI (at 4 mg/kg/day), as well as S. aureus 
including MRSA- bacteremia and right sided endocarditis (at 
6 mg/kg/day). An important randomized controlled clinical 
trial showed that daptomycin was not inferior to a β-lactam 
antibiotic or vancomycin for the treatment of patients 
with S. aureus bacteremia and right-sided endocarditis 
(Fowler et al 2006). However, in this trial daptomycin was 
associated with a high rate of microbiologic failure. It was 
also concerning that reduced susceptibility to daptomycin 
emerged among S. aureus isolates. This resonates with the 
clinical ﬁ  nding mentioned above that daptomycin resistant 
S. aureus populations appear to be linked to reduced 
vancomycin susceptibility, a phenomenon that needs further 
elucidation (Rose et al 2007b). The mechanism of resistance 
to daptomycin has not been fully explained, but there are 
speciﬁ  c mutations associated with nonsusceptible S. aureus 
strains (Boucher and Sakoulas 2007). Despite this, and 
because of its convenient once-a-day dosing, its bactericidal 
action, and its favorable safety proﬁ  le, the role of daptomycin 
in the clinic is expanding (eg, into the treatment of bone 
and joint infections) (Lalani et al 2008). Nevertheless, 
its superiority to vancomycin in the treatment of MRSA 
infections and its efﬁ  cacy in the treatment of infections 
caused by VRE has yet to be prospectively demonstrated. Of 
note, it is signiﬁ  cantly less potent against VRE than against 
MRSA or than other compounds (Table 2).
Tigecycline (Figure 1.12) is the sole representative of 
the class of glycylcyclines (Rose and Rybak 2006), deﬁ  ned 
by a glycylamido (tert-butyl) moiety attached to the original 
tetracycline molecule, making it impervious to the efﬂ  ux 
pumps (eg, tetA and tetB) that normally extrude tetracyclines Infection and Drug Resistance 2008:1 39
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from the bacterial cell. It also avoids the ribosomal protec-
tion proteins (eg, tet(O)). Since it is a tetracycline, it also 
binds to the 30S ribosomal subunit blocking the entry of 
amino-acyl tRNA and ultimately inhibiting protein synthesis. 
It has a broad spectrum of activity that includes MRSA and 
enterococci (including VRE) and also enterobacteria and 
anaerobes. The adequate performance of tigecycline in clini-
cal trials support its use in the treatment of polymicrobial 
CSSSI and intra-abdominal infections (Babinchak et al 2005; 
Ellis-Grosse et al 2005). Although it is known to be inactive 
against Pseudomonas and Proteus spp. (Dean et al 2003; 
Visalli et al 2003), tigecycline held promise as a treatment 
against multidrug-resistant enterobacteria and Acinetobacter 
spp. However, the results of the clinical experiences in the 
treatment of Gram-negatives recently published are disap-
pointing (Anthony et al 2008; Navon-Venezia et al 2007). 
Tigecycline remains an option against MRSA and entero-
cocci CSSTI (Munoz-Price et al 2006).
Of note, tigecycline has excellent penetration into 
tissues. Experiments with radiolabeled antibiotic demon-
strated the AUC value in spleen, liver, and kidney to be at 
least eight times higher than in plasma. Tissue exposure 
in lung was more than four times higher than in plasma, 
whereas in bone it was several hundred-fold higher. It 
appears that tigecycline is primarily the subject of biliary 
excretion. Approximately 30% of the tigecycline is excreted 
unchanged in the urine (Meagher et al 2005). Despite the 
above data, trials involving urinary tract infections were 
abandoned (Livermore 2005). Therefore, more studies are 
needed before tigecycline can be recommended for that 
indication (Cunha et al 2007; Krueger et al 2008). The 
proﬁ  le of adverse effects with tigecycline is remarkable for 
nausea and vomiting in a large proportion of patients, as 
well as increases in the blood urea nitrogen (BUN) consis-
tent with the catabolic effects of tetracyclines. It must be 
noted that the original tetracyclines (ie, minocycline and 
doxycycline) have re-emerged to play a major role in the 
therapy against MRSA, mostly in the treatment of uncom-
plicated skin and soft tissue infections and as adjuvants in 
chronic suppressive regimens (Ruhe et al 2005).
On the horizon
Iclaprim (Figure 1.13), a novel compound, represents a 
departure from a preexisting class of antibiotics, dihydro-
folate reductase (DHFR) inhibitors. The best representa-
tive of this class is the diaminopyrimidine trimethoprim 
(TMP), currently used in the clinic in combination with 
sulfamethoxazole (SMX). TMP/SMX largely retains activ-
ity against MRSA and is very often used in the treatment 
of uncomplicated skin and soft tissue infections. However, 
resistance to TMP does occur, resulting from a single amino 
acid change in the active site of S. aureus DHFR that prevents 
the formation of hydrogen bonds with TMP. Iclaprim, also 
a diaminopyrimidine, incorporates a cyclopropyl group that 
allows for the formation of hydrogen bonds even in TMP 
resistant S. aureus (Schneider et al 2003; Hawser et al 2006). 
Furthermore, iclaprim is as equally effective as TMP in inhib-
iting DHFR in S. aureus and E. coli, but is an order of mag-
nitude more efﬁ  cient against DHFR from S. pneumoniae and 
Pneumocystis jiroveci. This translates into activity against 
MRSA, VISA, and VRSA, and against multidrug-resistant 
S. pneumoniae (β-lactam, macrolide, quinolone and TMP 
resistant). Iclaprim, like TMP, has adequate enteral bioavail-
ability (Kohlhoff and Sharma 2007; Laue et al 2007) and its 
clinical development is followed with interest.
A second class of DHFR inhibitors currently under 
development is that of dihydrophthalazine antifolates. Three 
compounds, BAL-30543, BAL-30544, and BAL-30545, 
have demonstrated activiy against MSSA, MRSA, VISA, 
and VRSA, and TMP-resistant S. aureus, as well as MDR-
resistant S. pneumoniae. Similar to other DHFR inhibitors, 
they can be administered enterally and parenterally with 
excellent bioavailability (47th ICAAC, Abstracts F1-934 
and 935, Chicago IL, 2007).
RWJ 416457, a novel oxazolidinone with a pyrrolopyr-
azolyl substitution, has been tested in vitro against a variety 
of organisms, including MRSA and VRE. It generally had 
two- to fourfold lower MICs than those of linezolid against 
most pathogens tested (Foleno et al 2007). Similarly, when 
tested against linezolid-resistant enterococci and S. aureus it 
demonstrated lower MICs than linezolid but only by a couple 
of dilutions, indicating that RWJ 416457 is susceptible to 
the same mechanism of resistance than linezolid, namely 
mutations in genes coding for the 23S rRNA (Livermore 
et al 2007).
Friulimicin (Figure 1.10), the natural product of Acti-
noplanes friulensis, is structurally similar to daptomycin 
and therefore is classiﬁ  ed as a cyclic lipopeptide. Their 
mechanism of action, however, seems to differ. Friulimicin 
prevents cell wall synthesis by forming a calcium dependent 
complex with the bacroprenol-phosphate carrier whereas 
daptomycin’s putative mechanism of action is the formation 
of pores that leads to extrusion of potassium and cell death. 
In general, friulimicin has a similar bactericidal activity 
as daptomycin against MRSA, S. pneumoniae and VRE, 
but typically its MICs are one dilution higher. The excep-Infection and Drug Resistance 2008:1 40
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tion is Streptococcus pyogenes for which friulimicin has a 
fourfold higher MIC (4–8 µg/ml). Despite sharing a similar 
structure, friulimicin does not demonstrate cross-resistance 
with daptomycin. Unlike daptomycin, it is not inhibited by 
pulmonary surfactant and it appeared effective in a murine 
S. pneumoniae pneumonia model, as well as in a S. aureus 
abscess model (47th ICAAC, Abstracts F1-1640, 1642, 1643, 
1647, 1651, 1652, Chicago, IL, 2007).
Api-1252 exploits a novel mechanism of action, the 
inhibition of bacterial enoyl-acyl carrier protein (enoyl-ACP) 
reductase (FabI). This compound is in development for the 
treatment of staphylococcal infections. In preliminary trials, it 
demonstrated potent in vitro activity against clinical isolates 
of MRSA (MIC90, 0.015 µg/ml), as well as Staphylococcus 
epidermidis (Karlowsky et al 2007).
CBR-2092 is a novel rifamycin-quinolone hybrid antibi-
otic in the preclinical stages of development for the treatment 
of MRSA. It has shown activity in animal models of endo-
carditis against quinolone resistant MRSA. (47th ICAAC, 
Abstract F1-2102 Chicago, IL, 2007).
Finally, in the ﬁ  eld of topical antibiotics, retapamulin 
(Figure 1.14) received FDA approval for the treatment 
of impetigo. A semisynthetic pleuromutilin derivative, it 
is active against MRSA, as well as Streptococcus spp. It 
inhibits protein synthesis by binding to the 50S portion of 
the ribosome in a different fashion than other antibiotics 
(blocks peptidyl transferase activity, and partially inhibits 
the binding of the initiator tRNA substrate to the ribosomal 
P-site), explaining the lack of cross-resistance (Yan et al 
2006; Champney and Rodgers 2007; Jacobs 2007; Oranje 
et al 2007). Another promising class of topical agents is that 
of diphenyl-ureas, active against MRSA and Streptococcus 
spp. and effective in murine models studying MRSA skin 
infection and nasal colonization (47th ICAAC, Abstract F1-
2094-2100 Chicago, IL, 2007).
Conclusion
The immediate conclusion after reviewing close to twenty of 
the antibiotics that are already in use or are in development 
for the treatment of infections caused by resistant Gram-
positive bacteria is that there are indeed many options. The 
state of the antibiotic pipeline for Gram-positive bacteria 
appears to be very healthy. This poses a stark contrast with 
the situation in the Gram-negative realm, where there are 
serious and widespread misgivings about the capacity and 
willingness of the pharmaceutical industry to continue to 
meet the medical needs posed by certain infectious patho-
gens (Talbot et al 2006). The ever present need for new 
antimicrobials is made more poignant by the emergence 
of resistance, which either has already been described for 
many of the agents discussed (Table 1) or is predictable and 
waiting around the corner.
It also seems that, despite or because of the many options 
available, deﬁ  ning the therapy of “choice” for serious Gram-
positive bacterial infections has become more difﬁ  cult than 
ever. This apparent paradox underscores the notion that 
the value of an antibiotic does not lie within its chemical 
structure but in the body of knowledge supporting its use. 
As illustrated in the above discussion on the continued utility 
of vancomycin, multiple considerations and points of view 
apply and there are no simple answers. We hope that similar 
discussions about the newer compounds can be made in the 
future, informed by sound microbiological, clinical, and 
epidemiological studies.
A single drug is not likely to dominate the future 
antibiotic landscape; different indications may call for 
different therapies, as suggested by the example of MRSA 
pneumonia and linezolid. Individual patient responses to 
antibiotics and the multiplicity of side effects will also be 
a consideration; pharmacogenomics will be a powerful 
tool to discern the best therapy for each patient (Davison 
and Barrett 2003). The longevity and robustness of our 
new armamentarium against Gram-positive bacterial 
infections will be determined by factors speciﬁ  c to each 
drug, such as effectiveness, convenience, cost, and emer-
gence of resistance, as much as by efforts in the general 
aspects of immunization, infection control, and antibiotic 
stewardship.
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